Submitted for publication August 22, 1988 The effects of cholecystokinin receptor antagonist, dipentyl-3,4-dichloroproglumide (DDP), on stimulated pancreatic and gastric secretion were studied in the rat. DDP dose-dependently inhibited cholecystokinin-stimulated amylase release from dispersed acinar cells. In uiuo, DDP inhibited cholecystokinin octapeptide-stimulated amylase and protein secretion.
DDP also inhibited pentagastrin-stimulated gastric acid secretion in vivo. Meal-stimulated acid output was decreased by 34% (DDP 400 pg/kg/hr) but responsiveness to histamine or parachlorophenyl-y-aminobutyric acid was unchanged.
INTRODUCTION
A number of compounds have been developed recently with activities as receptor antagonists for peptide hormones of the gastrointestinal tract. These compounds have exciting potential as probes for elucidation of control mechanisms of gastrointestinal function and for investigation of the role of gastrointestinal hormones in various disease states. Future therapeutic uses of specific receptor antagonists is an important prospect.
Among the amino acid derivatives, a series of glutaramic acid congeners have recently been reported which are potent antagonists of the pancreatic stimulatory actions of CCK in vitro [ll] . Several of the agents demonstrate greatly improved in vitro potency when compared to benzotript or proglumide. Glutaramic acid derivatives have been reported to inhibit binding of CCK to guinea pig gallbladder and to rat pancreatic tissues and brain [12, 131. Glutaramic acid derivatives have been reported by Niederau et al. to competitively inhibit the binding of CCK to dispersed rat acinar cells and to dose-dependently inhibit amylase release from dispersed cells [13] . The current study was designed to correlate in vitro and in uiuo activities of one of the most potent of these compounds, dipentyl-3,4dichloroproglumide, on CCK-stimulated pancreatic secretion. In addition, because of the close structural similarities between the active sites of the CCK and gastrin molecules, the specificity of this receptor antagonist for in uiuo experimentation was assessed by examining its effects on stimulated gastric acid secretion.
MATERIALS AND METHODS

Substances
A number of compounds have been described which DL -4 -(3,4 -Dimethylbenzoylamino) -5 -(di -n -pentyldemonstrate cholecystokinin (CCK) receptor antagonism amino)-5oxopentanoic acid (dipentyl-3,4dichloropro-in vitro. Four general classes of CCK receptor antagonists glumide-referred to subsequently in this text as DDP) have been recognized: (1) derivatives of cyclic nucleotides was a generous gift of Dr. I. Setnikar, Rotta Laboratorium, such as dibutyryl cyclic GMP; (2) fragments or analogs Milan, Italy. For in uiuo experiments, DDP was adminof the C-terminal region of CCK; (3) nonpeptide com-istered after it was dissolved in 0.9% NaCl. Cholecystopounds such as asperlicin, derived from Apergillus aUi-kinin octapeptide (CCK8; Peninsula Labs, Belmont, CA), aceus; and (4) amino acid derivatives such as benzotript and pentagastrin (Ayerst Laboratories) were prepared as or proglumide [l-8] . While the various agents have been solutions in 0.1% bovine serum albumin (Sigma Chemical useful for investigation of pancreatic function in vitro, Co., St. Louis, MO). Histamine (Eli Lilly, Indianapolis, most of these compounds have pharmacologic deficits IN), and para-chlorophenyl-y-aminobutyric acid (PCPwhich limit their use for in uiuo experimentation or for GABA, Geigy Pharmaceuticals, Summit, NJ) were distherapy. For example, both benzotript and dibutyryl cyclic solved in 0.9% NaCl. Liquid peptone meals (Bactopep-GMP are toxic at doses which achieve significant inhibtone; Difco Laboratories, Detroit, MI) were prepared at itory actions in uiuo [9] . CCK analogs and C-terminal 5% (w/v) concentrations; the osmolarity and pH of each peptide fragments require intravenous infusion and are meal were adjusted to 320 mOsm and 5.5 by addition of rapidly degraded in serum or blood [lo] . Benzotript and NaCl and 4 N HCl, respectively. All other chemicals and proglumide are limited by unacceptably low potencies.
supplies were purchased from Sigma. 
Isolated Pancreatic Acini
The method for preparation of isolated rat pancreatic acini is a modification of the methods of Amsterdam et al. [ 141 and Williams et al. [15] . Male Sprague-Dawley rats, weighing 200-250 g, were fasted for 16 hr before sacrifice. The pancreas was removed and carefully dissected free of nonpancreatic tissue. With a 25-gauge needle, the pancreas was injected with 5 ml of highly purified collagenase solution [Krebs-Ringer-Hepes buffer plus 0.1 mg/ml soybean trypsin inhibitor (Sigma), 0.1 n&f Ca2+, 11.1 mM glucose, and 0.1 mg/ml highly purified collagenase (Worthington Biochemicals)]. Pancreatic tissue was incubated for three periods of 15 to 30 min with collagenase solution at 37°C. The tissue was dissociated by forceful aspiration through three Pasteur pipets of decreasing size. Debris was removed by passage through Nitex gauge (200 pm). Isolated acini were centrifuged in 4% albumin and then resuspended in buffer. For dose-response studies, the acini were incubated with various concentrations of secretogogue and antagonists for 20 min at 37°C in a shaking water bath. Amylase release into the supernatant was assayed spectrophotometrically by a modification of the method described by Bernfeld [ 161. Amylase release was expressed as the percentage of total amylase present.
A Schild plot for inhibition of amylase release by DDP was calculated from CCK dose-response curves in the presence of increasing amounts of the inhibitor [ 171. For each shift in the dose-response curves, the ratios of the 50% inhibitory dose of CCK (ID& in the presence of DDP to CCK alone were calculated. The negative log of the molar doses of DDP were plotted against the respective IDso values. The least-squares method was used to find the regression line.
In Vivo Pancreatic Secretory Studies
In vivo effects of DDP on pancreatic exocrine secretion were examined in urethane-anesthetized animals. The National Research Council's Guide for Care and Use of Laboratory Animals was followed. After a 16-hr fast, rats were injected intraperitoneally with urethane (1.25 g/kg). The pancreas was exposed through a short midline incision. A small incision was made in the pancreatic duct just proximal to the duodenal wall; the duct was cannulated with polyethylene tubing. Bile-pancreatic juice was collected by gravity drainage in 30-min samples. Through a separate duodenal puncture site, a small polyethylene catheter was inserted for infusion of bile pancreatic juice at the rate of 1.5 cc/hr. The infused bile-pancreatic juice had been previously collected from normal rats. A 23-gauge needle was placed in the femoral vein for infusion of test substances; for those experiments in which more than one peptide or test substance was infused, bilateral femoral catheters were used.
Pancreatic secretory volume was recorded and samples of pancreatic secretion were assayed for protein and amylase. Protein content was determined by the method of Lowry et al. [ 181.
In viva Ch.stric Secretory &u&es
The effects of DDP on in vivo gastric acid secretion were studied using an acute gastric fistula preparation. After a 16-hr fast, rats were anesthetized with intraperitoneal urethane. The trachea was cannulated and the esophagus was ligated in the neck. Vagal nerve trunks were carefully preserved during esophageal ligation. Through a small midline incision, the stomach was exposed and a double-lumen gastric cannula was inserted via the forestomach. The pylorus was ligated. Venous access was achieved with femoral vein catheters. For studies that included intravenous or subcutaneous administration of test substances, the gastric lumen was rinsed with 20 cc of saline every 10 min. Acid production was measured by titration of the gastric rinse solution with 0.1 N NaOH to neutrality. For liquid meal studies, the meal was instilled at a volume of 10 ml. After 10 min, the test meal was evacuated, and the stomach was rinsed with 20 cc of saline. Acid production was measured for the liquid meal stimulus by titration to pH 5.5. Acid secretion was expressed as milliequivalents per 10 min.
Statistical Analysis
Data from in viva experiments were calculated as group means f SEM and were analyzed using a one-way analysis of variance. Significance was assumed for P values less than 0.05.
RESULTS
Effects on in Vitro Amylase Release
Increasing concentrations of CCK8 dose-dependently stimulated amylase release from dispersed rat acinar cells. Amylase release was maximal at 10-l' M, with decreased responses at higher concentrations (Fig. 1) . The CCK dose-response curve was shifted to the right in the presence of the CCK antagonist, DDP. The magnitude of the shift was related to the concentration of the antagonist. However, maximal amylase release, expressed as percentage of total amylase, was unaffected by increasing concentrations of DDP.
Analysis of the data by a Schild plot demonstrates that DDP acts as a competitive antagonist of CCK stimulation of amylase secretion (Fig. 2) . The Ki, determined from the intercept with the horizontal axis, was 3 X 10V7 M. The slope of the line was 0.93.
Effects on in Vivo Pancreatic Secretion
Increasing concentrations of CCKS, administered intravenously, dose-dependently increased pancreatic amylase output. Maximum amylase secretion was observed at a CCK dose of 1.1 hg/kg/hr, the highest dose employed. DDP administered intravenously for 30 min prior to CCK infusion did not alter basal protein or amylase output (Fig. 3) . However, the antagonist (at doses of 50 and 200 pg/kg/hr) caused significant inhibition of pancreatic amylase and total protein responses to CCK stimulation. The maximal pancreatic exocrine response to CCK stimulation was significantly decreased for all doses of DDP utilized (Fig. 3) . DDP at a dose of 400 pg/kg/hr was infused intravenously starting 30 min prior to administration of histamine (10 mg/kg subcutaneously) or PCP-GABA (4 mg/kg subcutaneously).
Effects on in Viuo Gastric Acid Secretion Increasing concentrations of pentagastrin, ranging from 1 to 64 pg/kg/hr caused dose-dependent increases in gastric acid output (Fig. 4) . Decreases in pentagastrin-stimulated acid secretion were noted in association with DDP administration (Fig. 5 ). These differences achieved statistical significance at a dose of 400 pg/kg/hr. At this dose, DDP nearly abolished the gastric acid response to all doses of pentagastrin tested. The in uiuo specificity of DDP was demonstrated by the absence of significant effect on acid secretion stimulated by histamine or by the vagal stimulatory agent PCP-GABA (Fig. 5) . However, DDP reduced 30-min peak acid output in response to a 5% liver meal by approximately 34% (Fig. 6) Among amino acid congener CCK receptor antagonists, proglumide and benzotript are the best characterized and have been used to treat human subjects with peptic ulcer disease [ 201. Both drugs have excellent clinical safety records, but low potency has limited their usefulness. DDP, which like proglumide and benzotript is a derivative of glutaramic acid, has a greatly increased inhibitory potency in uitro for CCK stimulation of pancreatic tissues. Niederau and co-workers have recently reported that the antagonist is 2500-4000 times more potent than proglumide in the inhibition of CCK%stimulated amylase release from dispersed rat acinar cells [13] . DDP demonstrated a similar increase in potency for inhibition of binding of '251-CCK to rat pancreatic acini. The compound displayed competitive kinetics in studies of rat tissues in vitro [21] . The current study confirms the ability of DDP to competitively inhibit CCK-stimulated amylase release from dispersed rat acinar cells. Increasing concentrations of the antagonist caused progressive shift of CCK dose-response curves to the right without altering maximal responses. Analysis of the data by the method of Schild yielded a Ki value of 3 X lo-' M. In addition, the study demonstrated that DDP effectively inhibited CCK-stimulated pancreatic exocrine secretion in vivo. Amylase secretion in vivo was dose-dependently inhibited by DDP; the degree of inhibition was significant for all doses of CCK when DDP was administered intravenously at a dose of 200 pg/kg/hr.
Because of the structural homology of the biologically active C-terminal regions of CCK and gastrin, it is not surprising that DDP also demonstrated inhibitory activity against pentagastrin-stimulated gastric acid secretion. Nearly total inhibition of acid secretion was observed at a dose of 400 pg/kg/hr.
This finding suggests that in vivo experiments that employ high-dose DDP blockade to demonstrate CCK-specific actions must be interpreted with caution. DDP did not affect acid responses to histamine or PCP-GABA [22] . In contrast, DDP inhibited gastric acid responses to a liver extract meal by approximately 34%. The inhibition-of-meal response was similar to that reported in rats by Goto and co-workers using a monoclonal antibody to gastrin [23] .
In conclusion, dipentyl-3,4dichloroproglumide is a potent inhibitor of CCK-stimulated pancreatic exocrine function, effective both in vitro and in vivo. However, the agent also demonstrated significant in vivo inhibition of pentagastrin-stimulated gastric acid secretion when higher doses were used. The antagonist may serve as a useful probe for the investigation of pancreatic and gastric pathophysiology.
In the future, the agent may have potential as a therapeutic agent for selected pancreatic disease, an exciting and important prospect.
